Trade Ideas

Actionable trade ideas with entry/stop/target and risk framing.

Search Articles
Jan 14, 2026

AIRO: Undervalued Optionality in a Misread Defense Growth Story

Long trade idea - clean balance sheet, attractive gross margins, catalytic market backdrop; trade the re-rating as execution improves

AIRO Group (AIRO) is a recently listed aerospace and autonomy platform whose equity appears discounted by the market because investors focused on head...

Trade Idea Long
F&G Annuities & Life, Inc.
Jan 14, 2026

F&G (FG) - Technical Weakness, Strong Balance Sheet: A Tactical Long with Defined Risk

Insurance cash flows and a below-book equity price make FG a high-conviction, tactical buy while technical pressure persists.

F&G Annuities & Life (FG) has been sold off through late 2025 into early 2026, but the company’s insurance economics - large asset base (~$96.1B), r...

Trade Idea Long
JPMorgan Chase & Co.
Jan 14, 2026

JPMorgan After Q4 - Cheap Relative to Earnings, But Watch Credit & Rates

Q4 beat on EPS, missed revenue; valuation looks attractive near $308, but policy and macro risks can reprice the stock quickly.

JPMorgan's Q4 print (01/13/2026) showed an EPS beat (5.23 vs 5.05 est.) but slightly softer revenue (45.80B vs 46.66B est.). At ~ $308.6 the shares tr...

Trade Idea Long
Salesforce, Inc.
Jan 14, 2026

Buy Salesforce on Agentforce Acceleration — Normalize FCF to Support a 14x Multiple

Market cap ~ $229B, revenue momentum and AI agent tailwinds argue for a re-rating; trade plan included.

Salesforce is trading at roughly $238.48 (last trade) and a market cap near $229B. Recent top-line strength (Q2 revenue $10.236B) plus accelerating in...

Trade Idea Long
3D Systems Corporation
Jan 14, 2026

3D Systems: A Tightening Cash Curve — Breakeven Could Trigger a Quick Rerate

Operational cash flow turning the corner — a low multiple, improving OCF and modest revenue base make a tactical long worth considering

3D Systems (DDD) is trading at multi-year low multiples despite sequential improvements in operating cash flow. With operating cash outflows shrinking...

Trade Idea Long
CRISPR Therapeutics AG
Jan 14, 2026

CRISPR Therapeutics - Patience Pays: Buy the Pullback, Trade the Catalysts

A high-risk, event-driven long with clear entry, stops and layered targets through 2026

CRSP is a volatile, binary biotech that now carries early commercial promise via a partnered product and a deep pipeline. Balance-sheet strength reduc...

Trade Idea Long
Dell Technologies Inc.
Jan 14, 2026

Dell Is Pricing In Memory Pain; Buy the Pullback for a Recovery Into AI Server Demand

Strong cash flow and an underappreciated AI/data-center runway offset near-term memory-cost headwinds — tactical long with clear entries and stops.

Dell's enterprise hardware franchise is producing steady operating cash and margins even as memory costs create headline risk. With Q2 FY2026 revenue ...

Trade Idea Long
Jan 14, 2026

CNQ: High-Yield, Capital-Light Energy Pick for 2026 — 9 Reasons to Own

Canadian Natural Resources as a top energy trade for 2026 — dividend momentum, wide asset mix, and deep value versus recent range.

Canadian Natural Resources (CNQ) is my top energy idea for 2026. The case rests on a resilient production base (heavy crude + bitumen + conventional g...

Trade Idea Long
Datadog, Inc. Class A Common Stock
Jan 14, 2026

Datadog Is a Strong Buy Again: Profitability Turning, Cash Flow Solid, AI Tailwinds Intact

Sequential revenue and margin improvement make DDOG an actionable long with defined stops and asymmetric upside.

Datadog's latest quarter (ended 09/30/2025) showed steady top-line growth, ~80% gross margins, positive net income and robust operating cash flow. The...

Trade Idea Long
ADMA Biologics, Inc.
Jan 14, 2026

ADMA Biologics: Why I’m Buying the Dip and My $26 Price Target

Plasma-derived margins are real, the balance sheet is stronger than headlines suggest, but legal and audit risk keep this a tactical, not a no-brainer, trade

ADMA Biologics (ADMA) is a commercial plasma biologics manufacturer showing expanding revenue, durable gross margins and positive operating cash flow....

Trade Idea Long
MPLX LP
Jan 14, 2026

MPLX: High Yield, Visible Distribution Growth, and a Reason to Buy on Pullbacks

Underappreciated cash flow + steady distribution hikes make MPLX an asymmetric income-growth trade for position investors

MPLX offers a compelling mix of an elevated yield (roughly 7% at current levels), visible distribution increases through 2025, and stable midstream ca...

Trade Idea Long
Palantir Technologies Inc. Class A Common Stock
Jan 14, 2026

Short Palantir Now: Don’t Get Caught in the AI Re-rate

AI rotation is real — Palantir looks richly priced for perfection. Short with tight risk control.

Palantir is profitable and cash-generative, but the stock is priced for flawless execution and continued multiple expansion. With the market rotating ...

Trade Idea Short